{"id":938434,"date":"2026-02-19T16:11:54","date_gmt":"2026-02-19T21:11:54","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update\/"},"modified":"2026-02-19T16:11:54","modified_gmt":"2026-02-19T21:11:54","slug":"ardelyx-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update\/","title":{"rendered":"Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update"},"content":{"rendered":"
\n

\n IBSRELA revenue grew 73% in 2025 to $274.2 million and total revenues reached $407.3 million
<\/em>\n <\/p>\n

\n Patient-first XPHOZAH strategy preserved access and drove growth in total dispenses<\/em>\n <\/p>\n

\n Development programs for new IBSRELA indication and next-generation NHE3 inhibitor launched<\/em>\n <\/p>\n

\n Company is well capitalized to meet current business objectives<\/em>\n <\/p>\n

\n Conference call scheduled for 4:30 PM Eastern Time<\/em>\n <\/p>\n

WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) — Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today reported financial results for the fourth quarter and full year ended December\u00a031, 2025, and provided a business update.<\/p>\n

\u201cThe results we delivered in 2025 reflect our team\u2019s hard work and disciplined execution to bring our medicines to more patients in need, underscored by significant IBSRELA growth, increased adoption of XPHOZAH and rapid advancement of our clinical development programs,\u201d said Mike Raab, president and chief executive officer of Ardelyx. \u201cAs we look to build on this strong momentum, we see 2026 as a pivotal opportunity to further evolve our business into a meaningful enterprise built on a broad, thoughtful portfolio of best-in-class medicines. Our long-term strategy remains clear and unwavering: to deliver novel therapies to patients with significant unmet medical needs and generate sustained value for shareholders.\u201d<\/p>\n

\n IBSRELA<\/strong>
\n
\n \u00ae<\/strong>
\n <\/sup>
\n (tenapanor) finishes 2025 with $274.2 million in revenue<\/strong>
\n
Revenue for IBSRELA in 2025 was $274.2 million reflecting 73% growth compared to the $158.3 million reported for the full year 2024. The company recorded $86.6 million in IBSRELA revenue in the fourth quarter of 2025, 61% growth compared to the same period of 2024 and an 11% increase compared to the third quarter of 2025.<\/p>\n

Ardelyx expects continued growth in 2026 and beyond, driven by increased depth and breadth of prescribing among target healthcare providers, increased engagement with patients with irritable bowel syndrome with constipation (IBS-C) as well as further improved prescription pull-through. Ardelyx expects full-year 2026 revenue for IBSRELA to be between $410 and $430 million, representing at least 50% growth compared to 2025. As a result of the significant momentum that IBSRELA has generated, the company expects IBSRELA to achieve $1 billion in annual revenue in 2029, with further growth thereafter.<\/p>\n

\n XPHOZAH<\/strong>
\n
\n \u00ae<\/strong>
\n <\/sup>
\n (tenapanor) finishes 2025 with $103.6 million in revenue<\/strong>
\n
Revenue for XPHOZAH in 2025 was $103.6 million reflecting year-over-year growth in total XPHOZAH dispenses, including an increased number of non-Medicare patients on therapy. The company also recorded $27.8 million in revenue in the fourth quarter of 2025.<\/p>\n

Ardelyx expects growth in 2026 to be driven by increased clinical conviction and writing among target healthcare prescribers. Ardelyx expects full-year 2026 XPHOZAH revenue to be between $110 and $120 million.<\/p>\n

\n Building a pipeline of important medicines<\/strong>
\n
The company advanced efforts to expand the eligible patient population for IBSRELA to include patients with chronic idiopathic constipation (CIC) and has launched a Phase 3 trial, ACCEL<\/a>, to assess tenapanor in patients with CIC, dosing the first patient in Q1 2026. Pending the outcome of the Phase 3 trial, Ardelyx intends to submit a Supplemental New Drug Application to the U.S. Food and Drug Administration (FDA) for the CIC indication. Enrollment in ACCEL is expected to be completed by the end of 2026 and topline readout is expected in the second half of 2027.<\/p>\n

Ardelyx also launched a development program for RDX10531, a next-generation sodium\/hydrogen exchanger 3 (NHE3) inhibitor, in 2025. The company is currently completing pre-clinical development activities in advance of an Investigational New Drug submission to the FDA in the second half of 2026 and initiation of a Phase 1 clinical trial thereafter.<\/p>\n

\n Other Corporate Developments<\/strong>\n <\/p>\n